Conditions: Ovarian Carcinoma Fallopian Tube Carcinoma Peritoneal Carcinoma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 7
Healthy volunteers: no

Brief summary:
To evaluate progression-free survival with two chemotherapy regimens on platinum-resistant/refractory ovarian and peritoneal carcinoma

Detailed description:
This study will evaluate progression-free survival (PFS)for the regimen of gemcitabine and bevacizumab with or without a platinum agent on platinum-resistant/refractory ovarian and peritoneal carcinoma

Arms:
arm 1: Platinum:

1. Carboplatin\* on day 1

   \*If a patient is allergic to carboplatin, then give
2. Cisplatin\*\* on day 1

   \*\*If a patient is allergic to cisplatin and carboplatin, then give
3. Oxaliplatin on day 1

Gemcitabine on day 1 only

Bevacizumab on day 1 arm 2: Gemcitabine on days 1 and 8

Bevacizumab on day 1

Interventions: intervention 1: Gemcitabine intervention 2: Bevacizumab intervention 3: Carboplatin intervention 4: Cisplatin intervention 5: Oxaliplatin
Intervention descriptions: intervention 1: Patient to receive gemzar intervention 2: Patient to receive avastin intervention 3: Patient to receive carboplatin intervention 4: Patient to receive cisplatin intervention 5: Patient to receive Oxaliplatin

Protocol document: